Hackensack Meridian Health Center for Discovery and Innovation to Host Genomic Medicine Symposium – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Hackensack Meridian Health Center for Discovery and Innovation (CDI), Feb 19

Newswise Nutley, N.J. (January 17, 2020) Genomic medicines groundbreaking treatments, and its future promise, will be the focus of a full-day symposium at the Hackensack Meridian Health Center for Discovery and Innovation (CDI) on Wednesday, February 19.

This emerging discipline for tailoring active clinical care and disease prevention to individual patients will be the focus of presentations given by eight experts from medical centers in the U.S.A. and Canada.

The Genomic Medicine Symposium convenes a diverse group of scientific experts who help serve as a vanguard for precision medicine, said David Perlin, Ph.D., chief scientific officer and vice president of the CDI. At the Center for Discovery and Innovation, we are working to make genomics a central component of clinical care, and we are delighted to host our peers and partners from other institutions.

The event is one-of-a-kind, said Benjamin Tycko, M.D., Ph.D., a member of the CDI working in this area, and one of the hosts. We are bringing together great minds with the hope it will help inform our planning for genomic medicine within Hackensack Meridian Health and inspire further clinical and scientific breakthroughs.

Cancer treatments, neuropsychiatric and behavioral disorders, cardiometabolic conditions, autoimmune disease, infectious disease, and a wide array of pediatric conditions are areas where DNA-based strategies of this type are already employed, and new ones are being tested and refined continually.

The speakers come from diverse medical institutions and will talk about a variety of clinical disorders in which prevention, screening, and treatment can be informed through genomic and epigenomic data.

Among the speakers are: Daniel Auclair, Ph.D., the scientific vice president of the Multiple Myeloma Research Foundation; Joel Gelernter, M.D., Ph.D., Foundations Fund Professor of Psychiatry and Professor of Genetics and of Neuroscience and Director, Division of Human Genetics (Psychiatry) at Yale University; James Knowles, M.D., Ph.D., professor and chair of Cell Biology at SUNY Downstate Medical Center in Brooklyn; Tom Maniatis, Ph.D., the Isidore S. Edelman Professor of Biochemistry and Molecular Biophysics, director of the Columbia Precision Medicine Initiative, and the chief executive officer of the New York Genome Center; Bekim Sadikovic, Ph.D., associate professor and head of the Molecular Diagnostic Division of Pathology and Laboratory Medicine at Western University in Ontario; Helio Pedro, M.D., the section chief of the Center for Genetic and Genomic Medicine at Hackensack University Medical Center; Kevin White, Ph.D., the chief scientific officer of Chicago-based TEMPUS Genetics; and Jean-Pierre Issa, M.D., Ph.D., chief executive officer of the Coriell Research Institute.

The event is complimentary, but registration is required. It will be held from 8 a.m. to 4:30 p.m. at the auditorium of the CDI, located at 111 Ideation Way, Nutley, N.J.

The event counts for continuing medical education (CME) credits, since Hackensack University Medical Center is accredited by the Medical Society of New Jersey to provide continuing medical education for physicians.

Hackensack University Medical Center additionally designates this live activity for a maximum of 7 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information, visit https://www.hackensackmeridianhealth.org/CDIsymposium.

ABOUTHACKENSACKMERIDIAN HEALTH

Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.

Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two children's hospitals - Joseph M. Sanzari Children's Hospital in Hackensack, K. Hovnanian Children's Hospital in Neptune; nine community hospitals Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital Carrier Clinic in Belle Mead; and two rehabilitation hospitals - JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick.

Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 34,100 team members, and 6,500 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.

The network's notable distinctions include having four hospitals among the top 10 in New Jersey by U.S. News and World Report. Other honors include consistently achieving Magnet recognition for nursing excellence from the American Nurses Credentialing Center and being named to Becker's Healthcare's "150 Top Places to Work in Healthcare/2019" list.

The Hackensack Meridian School of Medicine at Seton Hall University, the first private medical school in New Jersey in more than 50 years, welcomed its first class of students in 2018 to its On3 campus in Nutley and Clifton. Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer care when and where they need it.

Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.

For additional information, please visit http://www.HackensackMeridianHealth.org.

About the Center for Discovery and Innovation:

The Center for Discovery and Innovation, a newly established member of Hackensack Meridian Health, seeks to translate current innovations in science to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions. The CDI, housed in a fully renovated state-of-the-art facility, offers world-class researchers a support infrastructure and culture of discovery that promotes science innovation and rapid translation to the clinic.

Continue reading here:
Hackensack Meridian Health Center for Discovery and Innovation to Host Genomic Medicine Symposium - Newswise

6 charts break down 2019, the second-hottest year on record – Grist

This story was originally published by Mother Jones and is reproduced here as part of the Climate Desk collaboration.

On Wednesday, scientists from the National Oceanic and Atmospheric Administration and National Aeronautics and Space Administration released their combined study on 2019 weather trends around the world. The main takeaway was stark: 2019 was the second-warmest year on record, and the trend from Alaska to Antarctica has been one of steady warming. According to data from the two government agencies collected independently, then presented in tandem the last five years were the hottest in recent human history, with 2016 barely beating 2019 for first place.

The respective organizations covered much of the same ground, but both made some unique additions to the joint report. NASA, for example, contributed a global temperature uncertainty analysis tracking margin of error while NOAA added specific coverage of domestic heat and rain conditions for the year.

Get Grist in your inboxAlways free, always fresh

The Beacon Other choices

Ask your climate scientist if Grist is right for you. See our privacy policy

Notwithstanding the potential for major disruptive events a volcano, some sort of massive social action if setting those aside, Deke Arndt, chief of climate monitoring at NOAA, told reporters, the chances are well continue to climb at about the rate weve been climbing. Though the report contained no predictions beyond that one, their data illustrates that even though 2019 may have been an anomaly on the grand scale, if the scope were narrowed to the last decade, it was yet another example of how the planet is moving towards a hotter future.

Here are some of the most striking charts from the report:

According to data collected by NASA, and corroborated by NOAA, 2019 was the second-warmest year ever recorded. Thats 1.8 degrees Fahrenheit warmer than the average temperature of the Earth between 1951 and 1980.

Despite being collected independently of each other, there is remarkable consistency between the findings. On a given year, its normal for there to be some discrepancy, but Arndt says the data from 2019 were in complete agreement, showing a consistent increase in global average temperature since at least 1980. By presenting that data side by side, he notes, the findings of both are reinforced. Were measuring the same planet, and we do have slightly different methods, he said. It actually helps that we have slightly different ways in a checks and balances way to make sure our methods are solid.

According to Gavin Schmidt, the director of NASA Goddard Institute for Space Studies, the Arctic sea ice levels oscillate between March and September, when seasonal ice melting and expansion take place. In recent decades, the measurements of sea ice taken at those times have dramatically fallen, uncovering sections of Arctic ice that havent touched the open air on the earths surface in 50,000 years.

Across the United States, mean temperatures in 2019 also were above average. The differences were particularly dramatic in the American South, where large swathes of Georgia, Virginia, and North Carolina saw record heat.

Yet it was Alaska that saw the most dramatic deviation from the norm. Average temperatures in the state in 2019 were 32.2 degrees Fahrenheit, more than 6 degrees higher than the cumulative average from 1925 to 2000.

These findings are jarring and come during a long campaign of climate change erasure and denialism from the Trump administration. Though the organizations have been pulled onto the political chessboard in the past by President Donald Trump, both scientists were clear about the fundamental cause of the warming temperatures: Certainty that the trend is the result of human behavior is at near 100 percent, says Schmidt. All the trends are anthropogenic at this point.

Never miss a beat! Sign up for The Beacon today. Its your daily dose of good news coupled with all the latest environmental coverage from Grist. Stop freakin and sign up for The Beacon. Youre gonna love it.

Originally posted here:
6 charts break down 2019, the second-hottest year on record - Grist

Worth Watching: New ‘Curb’ and ‘Avenue 5’ on HBO, Australia Before the Fires in ‘Seven Worlds,’ ‘9-1-1: Lone Star,’ Cynthia Erivo in ‘Outsider’ -…

A selective critical checklist of notable weekend TV:

Curb Your Enthusiasm (Sunday, 10:30/9:30c, HBO) We're pretty, pretty enthused about the return, after two long years, of Larry David's deliciously cringe-worthy farce of bad behavior and inevitable consequences. We have no idea what will set Larry off in this long-awaited 10th season, but we'll settle for nothing less than scorched-earth comedy. Among the celebrity guests said to risking Larry's ire this season: Vince Vaughn, Jon Hamm, Mila Kunis, Fred Armisen, Timothy Olyphant (who's having a good year as The Good Place fans know) and Ed Begley Jr.

Curb is paired for a solid comedy hour with Avenue 5 (Sunday, 10/9c), the latest from Veep provocateur Armando Iannucci. The knockabout sci-fi spoof, set aboard an ill-fated luxury space cruise ship to Saturn, stars a frenetically droll Hugh Laurie (Veep, House) as captain-in-uniform-only Ryan Clark, who's ill-equipped to handle life-and-death crises when the Avenue 5 vessel goes disastrously off course, stranding a hapless crew and thousands of disgruntled passengers among the stars. Josh Gad co-stars (in an unflattering blond mop) as the ship's spoiled and clueless owner, and Silicon Valley's Zach Woods steals every scene as the chirpily and perversely nihilistic head of customer relations. All aboard! (See the full review.)

Seven Worlds, One Planet (Saturday, 9/8c, BBC America, AMC, IFC, SundanceTV): Sounds like science fiction, but this visually enthralling series is the latest from BBC Studio's Natural History Unit, capturing wildlife on each of Earth's seven continents. To call attention to relief efforts from the fires that have captured the world's alarmed attention, the network has shifted the series' episode order to premiere with "Australia." It's almost too painful to behold as you can't help wondering if the animals on display (filmed long before the wildfires began) could have survived the recent conflagrations. Among the rare sights captured by BBC's crews: a dingo giving chase to kangaroos and bringing its bounty back to her pups.

9-1-1: Lone Star (Sunday, 10/9c, 7/PT, Fox): Surely you knew this was coming. As inevitable as the tides, one TV hit clones another, and as you might expect, things blow up real good in Texas as Ryan Murphy's outrageous emergency melodrama spins off with an Austin offshoot. In the opener, following the NFC Championship game (expect lots of promos), a tragic explosion wipes out most of a local firehouse, and six months later, New York transplant Owen Strand (Rob Lowe, making clever sport of his metrosexual image) is recruited to rebuild the Engine and Ladder 126 crew. Captain Owen has his own issues, including a health crisis and a gay firefighter son (Ronen Rubinstein) in recovery, but soon sets about hiring the most diverse team imaginable Muslim? Check; Trans? Check while touting skin-care and hair protocols. The action scenes, as always, are impressively produced, but the emotional load of Lone Star is carried by True Blood's Jim Parrack as Judd, the original house's sole survivor, who needs to convince Owen and himself that his PTSD won't get in the way of doing the job.

The Outsider (Sunday, 9/8c, HBO): Oscar-nominated Cynthia Erivo (Harriet) makes her initial appearance as "the one and only" Holly Gibney a Stephen King character familiar from the Mr. Mercedes trilogy a quirky but intuitive savant of an investigator called in on the mystifying investigation. When Ralph (Ben Mendelsohn) informs her, "I have no tolerance for the unexplainable," she replies, "Well then, sir, you'll have no tolerance for me." We beg to differ. She's just what The Outsider needs, especially when belligerent deputy Jack Hoskins (Marc Menchaca) has a fateful encounter with the lurking menace, and fatherless Jessa Maitland (Scarlett Juniper Blum) conveys warning messages from her eerie night visitor to stop the hunt.

Sanditon (Sunday, 9/8c, PBS, check local listings at pbs.org): The Jane Austen-inspired Masterpiece continues to build on the undeniable sparks between Charlotte (Rose Williams) and the aloof Sidney (Theo James) with plot twists bringing them together often enough that he declares, "Seems I cannot escape you." Set pieces include a demonstration of a futuristic "shower bath" and a construction injury that causes Sidney to consider Charlotte as more than a distracting ornament.

Vienna Blood (Sunday, 10/9c PBS, check local listings at pbs.org): If your appetite for British mystery is insatiable, you might relish this stiff and derivative series, set in 1906 Vienna. Its your typical mismatched detective team, with gruff Viennese Detective Inspector Oskar Rheinhardt (Juergen Maurer) barely tolerating the boyish sidekick forced upon him: British student, and Freud acolyte, Max Liebermann (Matthew Beard), whose newfangled study of human behavior could help the Inspector, if only hed listen. Their first case, continuing next week, involves the murder, possibly supernatural, of a beautiful but devious medium.

Awards Season: The countdown to the Oscars continues with the 26th Annual Screen Actors Guild Awards (Sunday, 8/7c, 5/PT, TNT and TBS), with awards for film and TV. This year's SAG Life Achievement Award goes to The Irishman's Robert De Niro, presented by Leonard DiCaprio. Among the TV categories are drama ensemble cast (Big Little Lies, The Crown, Game of Thrones, The Handmaid's Tale and Stranger Things are nominees) and comedy ensemble (Barry, Fleabag, The Kominsky Method, The Marvelous Mrs. Maisel and Schitt's Creek are nominated).

Earlier in the evening, PBS broadcasts the Great Performances presentation of Movies for Grownups Awards with AARP The Magazine (6/5c, check local listings at pbs.org), filmed earlier this month, with Tony Danza hosting and Annette Bening receiving the Career Achievement Award from Billy Crudup. Among the highlights: Diane Ladd presenting the supporting actress award to her daughter Laura Dern for her role in Marriage Story.

Inside Weekend TV: To honor the late Buck Henry, a popular performer and guest host in early seasons of Saturday Night Live, the network repeats a first-season episode from 1976 (Saturday, 10/9c), with Henry hosting and Bill Withers as musical guest The road to the Super Bowl is determined by the winners of the AFC Championship Game (Sunday, 3:05/2:05c, CBS), with the Kansas City Chiefs taking on the Tennessee Titans; and the NFC Championship Game (Sunday, 6/5c, Fox), where the San Francisco 49ers are favored over the Green Bay Packers Hulu becomes the streaming home of one of FX's very best series, Justified, with all six seasons of U.S. Marshal Raylan Givens' (Timothy Olyphant) exploits available on Sunday. Won't the judge from The Good Place be thrilled? Building anticipation for the fifth and next-to-last season of Better Call Saul, returning in late February, AMC kicks off a Breaking Bad marathon with the first season airing in its entirety Sunday, starting at 4/3c. More seasons follow on successive Sundays In the season finale of Showtime's Ray Donovan (Sunday, 8/7c), Ray (Liev Schreiber) finally learns the truth about his beloved sister Bridget's death, just in time for Mickey's (Jon Voight) greedy shenanigans triggering a showdown between the Donovans and the Sullivans. As the saying goes, there will be blood. Or it wouldn't be Ray Donovan.

View original post here:
Worth Watching: New 'Curb' and 'Avenue 5' on HBO, Australia Before the Fires in 'Seven Worlds,' '9-1-1: Lone Star,' Cynthia Erivo in 'Outsider' -...

DeepMind Discovers AI Training Technique That May Also Work In Our Brains – Unite.AI

The human brain often recalls past memories (seemingly) unprompted. As we go throughout our day, we have spontaneous flashes of memory from our lives. While this spontaneous conjuration of memories has long been of interest to neuroscientists, AI research company DeepMind recently published a paper detailing how an AI of theirs replicated this strange pattern of recall.

The conjuration of memories in the brain, neural replay, is tightly linked with the hippocampus. The hippocampus is a seahorse-shaped formation in the brain that belongs to the limbic system, and it is associated with the formation of new memories, as well as the emotions that memories spark. Current theories on the role of the hippocampi (there is one in each hemisphere of the brain), state that different regions of the hippocampus are responsible for the handling of different types of memories. For instance, spatial memory is believed to be handled in the rear region of the hippocampus.

As reported by Jesus Rodriguez on Medium, Dr. John OKeefe is responsible for many contributions to our understanding of the hippocampus, including the hippocampal place cells. The place cells in the hippocampus are triggered by stimuli in a specific environment. As an example, experiments on rats showed that specific neurons would fire when the rats ran through certain portions of a track. Researchers continued to monitor the rats even when they were resting, and they found that the same patterns of neurons denoting a portion of the maze would fire, although they fired at an accelerated speed. The rats seemed to be replaying the memories of the maze in their minds.

In humans, recalling memories is an important part of the learning process, but when trying to enable AI to learn, it is difficult to recreate the phenomenon.

The DeepMind team set about trying to recreate the phenomenon of recall using reinforcement learning. Reinforcement learning algorithms work by getting feedback from their interactions with the environment around them, getting rewarded whenever they take actions that bring them closer to the desired goal. In this context, the reinforcement learning agent records events and then plays them back at later times, with the system being reinforced to improve how efficiently it ends up recalling past experiences.

DeepMind added the replaying of experiences to a reinforcement learning algorithm using a replay buffer that would playback memories/recorded experiences to the system at specific times. Some versions of the system had the experiences played back in random orders while other models had pre-selected playback orders. While the researchers experimented with the order of playback for the reinforcement agents, they also experimented with different methods of replaying the experiences themselves.

There are two primary methods that are used to provide reinforcement algorithms with recalled experiences. These methods are the imagination replay method and the movie replay method. The DeepMind paper uses an analogy to describe both of the strategies:

Suppose you come home and, to your surprise and dismay, discover water pooling on your beautiful wooden floors. Stepping into the dining room, you find a broken vase. Then you hear a whimper, and you glance out the patio door to see your dog looking very guilty.

As reported by Rodriguez, the imagination replay method doesnt record the events in the order that they were experienced. Rather, a probable cause between the events is inferred. The events are inferred based on the agents understanding of the world. Meanwhile, the movie replay method stores memories in the order in which the events occurred, and replays the sequence of stimuli spilled water, broken vase, dog. The chronological ordering of events is preserved.

Research from the field of neuroscience implies that the movie replay method is integral to the creation of associations between concepts and the connection of neurons between events. Yet the imagination replay method could help the agent create new sequences when it reasons by analogy. For instance, the agent could reason that if a barrel is to oil as a vase is to water, a barrel could be spilled by a factory robot instead of a dog. Indeed, when DeepMind probed further into the possibilities of the imagination replay method, they found that their learning agent was able to create impressive, innovative sequences by taking previous experiences into account.

Most of the current progress being made in the area of reinforcement learning memory is being made with the movie strategy, although researchers have recently begun to make progress with the imagination strategy. Research into both methods of AI memory can not only enable better performance from reinforcement learning agents, but they can also help us gain new insight into how the human mind might function.

View post:
DeepMind Discovers AI Training Technique That May Also Work In Our Brains - Unite.AI

Cuba’s revolutionary cancer vaccine builds bridges between the island and the United States – AL DIA News

Despite the fact that Donald Trump's government is determined to continue sanctioning Cuba - the charter flights from the U.S. to nine Cuban airports were suspended last week because of the country's support for Maduro's regime, according to statements by Secretary of State Mike Pompeo - the collaboration between the United States and the island continues, at least on scientific matters. And this should not surprise us, taking into account the great medical advances made by Cuban professionals in the treatment of various types of cancer.

This is what we'll be able to witness in "Cuba's Cancer Hope," a documentary by Llew Smith that will be released next April by PBS and that sheds light on CimaVax, a revolutionary treatment against lung cancer that prolongs the life of patients in very advanced stages and that the Center of Molecular Immunology (CIM) in Habana has taken more than twenty years to develop.

In fact, the results are so encouraging that the Roswell Park Comprehensive Cancer Center in New York soon joined the project and will be the first U.S. institution to conduct a clinical trial of the drug produced on the island.

"The future of our country must necessarily be a future of men of science and thought, because that is precisely what we are sowing most," Fidel Castro, 1960.

Llew Smith himself was one of the volunteers to test this pioneering treatment, according to Prensa Latina, and his results, which were made known two years ago, will be part of the documentary.

"The wonderful thing about working with our Cuban colleagues is that they really believe, in their heart of hearts, that medical care is a human right," said Dr. Kevin Lee, director of the Roswell Park immunology department, in a dialogue with the press, praising the medical advances being made in Cuba and its "great potential to treat and prevent cancer of various kinds."

Cuba a pioneer in science

Biotechnology is one of the most developed branches of Cuban science, which began to be promoted in 1980, when Fidel Castro's government created a group dedicated to the production of interphenon, a possible cancer drug, in addition to promoting scientific parks.

This is a commitment to progress that the current president of Cuba, Miguel Daz-Canel Bermdez, acknowledged to Castro on the occasion of the documentary, and which the late revolutionary leader already advocated in a speech made in 1960when he said:

"The future of our country must necessarily be a future of men of science and thoughtbecause that is precisely what we are sowing most."

But the CimaVax is not the only discovery of Cuban scientists, whose achievements can be traced in the history of the island:

In 1881, the scientist Carlos Juan Finlay was the discoverer of the agent that transmits yellow fever, the Aedes aegypti mosquito, which made it possible to clean up the areas invaded by this infectious agent and which, in the end, has prevented millions of deaths.

"The wonderful thing about working with our Cuban colleagues is that they truly believe, deep in their hearts, that medical care is a human right," Dr. Kevin Lee from Roswell Park.

Also at Cuba's Center for Genetic Engineering and Biotechnology (CIGB), Heberprot-P was developed, a unique drug that prevents the amputation of diabetic feet by healing ulcers.

In addition, Cuba was recognized by WHO as the first country in the world to eliminate mother-to-child transmission of HIV.

The documentary "Cuba's Cancer Hope" also includes other therapies being experimented with on the island, specifically for the treatment of different types of cancer, which once again confirms thatscientific advances are breaking down the walls that apparently separate us.

See the original post here:
Cuba's revolutionary cancer vaccine builds bridges between the island and the United States - AL DIA News

Scientists find powerhouses that fight tumours from within – Digital Journal

Lurking deep inside some tumours are "factories" full of immune cells that help the body fight a rearguard action against cancer and are key to helping some patients recover, new research has shown.

In recent years, doctors have turned to a new treatment for cancer, immunotherapy, which works by leveraging the body's immune system to fight tumours.

The technique has largely focused on white blood cells called T-cells, which are "trained" to recognise and attack cancer cells.

But the innovative treatment only works well for around 20 percent of patients, and researchers have been trying to understand why some people respond better than others.

Three papers published on Thursday in the journal Nature point the way, identifying a key formation inside some tumours: tertiary lymphoid structures (TLS).

These structures function like "factories or schools" for immune cells that help the body fight cancer, said Wolf H. Fridman, a professor emeritus of immunology at the Cordeliers Research Centre of the Paris Descartes University medical school, who helped lead one of the studies.

"The cells need to be educated in schools, which are the tertiary lymphoid structures," where they effectively learn to recognise and attack cancer cells, Fridman told AFP.

- No longer 'innocent bystanders' -

Key to the findings is that T-cells are far from the only immune cells capable of taking the fight to cancer, with researchers finding the TLS were full of B-cells, a kind of immune cell that produces antibodies.

"We have been T-cell addicts for 15 years in cancer," Fridman said with a laugh.

"We analysed these sarcomas to see what groups they had and what's striking is that these B-cells appeared."

Beth Helmink, a fellow in surgical oncology at the University of Texas's MD Anderson Cancer Center who worked on a second study, said the research changed perceptions of the role of B-cells in immunotherapy.

"Through these studies, we find that B-cells are not just innocent bystanders, but are themselves contributing in a meaningful way to the anti-tumour immune response," she said in a statement issued by the Center.

The discovery is something of a surprise, as an abundance of B-cells in cancer patients has sometimes been seen as a marker for poor prognosis.

But the studies found that patients with high levels of B-cells inside TLS in their tumours were more likely to respond well to immunotherapy.

"This series of studies are exciting because they represent real progress in the treatment of different types of cancer," said Louisa James, a lecturer in immunology at Barts and the London School of Medicine and Dentistry, Queen Mary University of London.

"In the short term, these results provide a new tool to help predict which patients are likely to benefit from treatment with immunotherapy and may also pave the way for improved treatments in the future," added James, who was not involved in the studies.

- Improving cancer treatment -

There are still many unanswered questions, including why the structures form in some tumours and not others.

And while it now seems clear that B-cells inside the structures play a key role in the success of immunotherapy, scientists are not sure precisely how.

It may be that the B-cells are on the frontlines, producing antibodies that attack cancer cells efficiently.

Or they may be bolstering T-cells, or perhaps doing both.

And not all TLS are created equal: the researchers found three categories, but only one type was "mature" enough to churn out cancer-fighting immune cells.

The research opens several promising avenues, the authors said.

Initially, it could help doctors screen patients to see which are most likely to respond well to immunotherapy.

And eventually, the research could mean more patients are successfully treated with the technique, said Goran Jonsson, a professor of oncology and pathology at Lund University in Sweden who worked on a third study.

"If we come up with a treatment that could enhance TLS formation, we could combine this with current immunotherapy regimens," he told AFP.

"Most likely this would lead to more patients responding to immunotherapy."

More here:
Scientists find powerhouses that fight tumours from within - Digital Journal

PhD life at the National Heart and Lung Institute | Imperial News – Imperial College London

Throughout the year the NHLI welcomes postgraduate research students who are progressing their careers in respiratory, vascular and cardiac sciences.

As every pathway to a PhD is different, we thought we would ask some students about their individual PhD journeys - from finding funding to advice they would give to someone thinking about applying for their own PhD.

First up, some of our respiratory students; Helen Stoelting, Lauren Headley, Karim Boustani, Nicoletta Bruno and Kunyuan Tian.

Helen My PhD centres around remodelling of the lung during asthma or allergic airway disease during early life, looking at both school-age children with asthma, but also pre-school wheezing in the chest which happens before that. A lot of children who have pre-school wheeze go on to develop asthma later in life, but some of them dont and at the moment we dont really know why that is.

Lauren - The methods of diagnosing and assessing asthma are pretty complicated and can be invasive and arent always accurate. So for me, the goal is to make a sampling method where we can just analyse it and tell people you need to be on this medication or this isnt going to work for you, just to simplify the process, making it much easier for patients and doctors and ultimately not see people suffer.

Karim - For my PhD Im looking at the role the antibody response plays in asthma and idiopathic pulmonary fibrosis (IPF) a lung disease that scars the lungs - and specifically why some types of antibodies are increased in patients with these diseases. I want to investigate why we find some types of B cells in the airways in the first place. If we can understand how these cells are contributing to inflammation and disease, we can hopefully target them with treatments.

Nicoletta - Im looking at steroid resistant asthma in particular, both in animals and humans. Im looking at the asthma types that are not strictly related to allergy and that are more resistant to the current therapies. Its more about identifying which mechanisms are going on because theres not much known about it, and when we learn more it will make a difference.

Kunyuan - Im looking at genetics and environment, recreating the onset of pre-school wheeze and the progression to asthma. The approach of my project is to set up an animal model using a virus to induce a viral response which will make the mice susceptible to asthma.

Karim - I am funded by an Asthma UK studentship as part of the Asthma UK Centre in Allergic Mechanisms of Asthma. After completing my MSc in Immunology at Imperial, I knew I wanted to study respiratory immunology at PhD level so I decided to apply.

Helen - The British Lung Foundation (BLF). My MSc research project supervisor already had funding secured for PhD students through her larger research grant and she helped guide me through the application process which was really helpful.

Lauren - I went on the FindaPhD website which found my MRC/Asthma UK joint PhD on it. It was one of the more straightforward applications Ive done. I had to send over my CV then have a Skype interview. How easy it is all depends on the funding youre applying for and the research group.

Kunyuan - My funding is from Asthma UK which I came across on the British Society of Immunology website. I think the scholarship was also advertised on the Imperial website too. I found the application process very straightforward. I didnt actually apply for this one initially but it was suggested to me that I apply for this PhD instead. I didnt think I was ready for this but when I had a closer look into it, I thought it sounded really interesting so it all worked out well.

Nicoletta - I found my MRC-Asthma UK studentship on the FindaPhD website. It was a fairly easy application process I just had to send a cover letter and my CV, and the interview was quite straightforward compared to other interviews Ive had.

Nicoletta - I studied my undergraduate degree in Biotechnology in Bologna, Italy, then I completed a MSc in Pharmaceutical Biotechnology in both Bologna and in Munich, Germany. I then worked as a research assistant in Cambridge at the Sanger Institute for two years before deciding that I wanted to do a PhD.

Helen - I did my undergraduate degree in Molecular Biomedicine at the University of Bonn in Germany and then I took a year out to do some internships at Bayer, a German biomedical company, and also worked in some university labs. This was a really helpful experience as it made me realise that I dont want to work in industry! I really enjoyed the project I did as part of my MSc in Immunology at Imperial. I had half a year of lectures and then completed my research project with Professor Clare Lloyd, whose group I am working in now.

Lauren - Before coming here I did my undergraduate degree at Kings College London which I extended into an MSci that was Integrated Physiology and Pharmacology for Research. However in order to do the BSc I had to do an Access course as I didnt actually have A Levels. I applied to a few universities for two different courses and I got offers from Kings and London Southbank which I thought was miraculous. It always seemed like it was A Levels or nothing, I was offered a place and I really enjoyed it.

Karim - I did my undergraduate degree London in Biochemistry at Kings College London and then I moved to Imperial to do an MSc in Immunology.

Kunyuan - When I was at high school in Singapore I decided that I wanted to study at a university in London so I applied for an undergraduate degree in Biomedical Sciences at University College London. I then did my MSc in Immunology here at Imperial and was a research assistant over at Imperial Colleges Hammersmith campus before starting my PhD.

Karim - I was already at Imperial for a year doing my MSc and I really liked it, and I knew I wanted to work within the field of immunology and lung inflammation. I knew Imperial had an excellent department so I thought Id apply.

Helen - It was actually more down to chance! I knew I wanted to study Immunology and in Germany there are a couple of universities that are renowned for Immunology, and one of those was where I did my undergraduate degree. I knew I didnt necessarily want to stay in the same city or at the same university so I started applying to places abroad and Imperials MSc just looked really interesting. They had a scholarship which was easy to apply for, and even though I didnt get it, I still came and I dont regret it.

Lauren - After completing my BSc in Pharmacology at Kings College London I actually had a PhD lined up in Australia. It was my dream to go out there but my husband said he didnt want to go! I told him that I would apply for this PhD at Imperial, thinking I was never going to get it so we could still go to Australiabut then I ended up getting it! Its been such an amazing opportunity; I never could have dreamed of coming here.

Nicoletta - Its quite funny actually, I applied and didnt really know that Imperial had such a good reputation for research! It was only once I started that I realised how lucky I was.

Helen - Its difficult to say now because Im still quite early in, but I think your heart has to be in it. There will be some difficult times somewhere along the line and if youre not enjoying research, dont do it. But I do think anyone can do it if you set your mind to it.

Karim - The advice that I would give to anyone thinking about doing a PhD would be to get a feel of the lab and supervisor beforehand if possible. If you can, go and meet with the principal investigator, go for an informal chat, go and see the labs, and see if they have all the equipment and funding you might want or need.

Nicoletta - It needs commitment and it can be stressful but its worth it. Its good because you keep challenging yourself all the time and you have to keep up to date on what everyone else is doing. You need to be motivated because you dont get paid much and you still have to work at weekends. But you get to work with clinicians and thats quite unique as you dont get to do that with many other places in Europe. Here you get clinicians working alongside pure scientists and you can learn from each other.

Kunyuan - Talk to postdocs because they are in a really interesting position theyve already done their PhD so can talk about their experience and at the same time they are still working up the ladder, so they are a very good source of advice.

Lauren - Go for it! The skills that you learn are so transferable, and if you enjoy learning and education, a PhD is perfect.

Continue reading here:
PhD life at the National Heart and Lung Institute | Imperial News - Imperial College London

Netanyahu and the Anatomy of a Constitutional Crisis – Lawfare

Amidst a flurry of constant political maneuvering, intense legal debate and multiple Supreme Court cases, Israel has been stuck in political and constitutional deadlock for nearly a year. For the first time in its history, Israel will hold a third parliamentary election in the span of just 12 months after the previous rounds failed to produce a viable government. And also for the first time, the Israeli prime ministers office is occupied by an individual who is facing multiple graft charges involving offenses directly related to his position but refuses to resign.

Prime Minister Benjamin Netanyahu insists on running for reelection, and he still maintains robust support within his political party, the Likud. Israeli politics have thus become inextricably entangled in his legal predicament.

Israels attorney general, Avichai Mandleblit, has found himself in the untenable role of both Netanyahus prosecutor and his advocate: Mandelblit personally authorized Netanyahus indictment after lengthy deliberations, but he has also represented the government at the Supreme Court in multiple cases stemming from that same indictment. Several of these cases have challenged Netanyahus competence to serve as prime minister, while others pertain to Netanyahus effort to secure parliamentary immunity from indictment.

So far, the attorney general has refused to articulate his position on key constitutional issues raised by the current situation, although he has determined that Netanyahu may stay on as caretaker prime minister until the elections. His silence contributes to the stalemate: These are uncharted waters, and there is little legal clarity about what Israels constitutional law requires in this situation.

Many questions need answering. One category relates to Netanyahus current effort to secure parliamentary immunity from indictment. Is Netanyahu eligible for parliamentary immunity from prosecution while he remains in office? Will he be granted parliamentary immunity as a practical and political matter? Would the Supreme Court uphold a decision by the Knesset, the Israeli parliament, to grant him immunity?

Another set of questions has to do with Netanyahus substantive competence to serve as prime minister under indictment. Can Netanyahu even run for reelection under indictment? Perhaps most consequentially, if Netanyahu secures the largest number of recommenders for prime minister in the Knesset after the March elections, may Israels president, Reuven Rivlin, assign him the mandate to form a governmentdespite Netanyahus failure to put together a governing coalition in two previous rounds, and notwithstanding the indictment? If Netanyahu succeeds in forming a government, can he be judicially removed?

In what follows I consider recent developments and the stakes involved in addressing some of these legal questions. For additional detailed analysis, in Hebrew, also see this opinion from the Israel Democracy Institute.

The Immunity Standoff

Like any other member of the Knesset, the prime minister is eligible to seek parliamentary immunity from criminal indictment. Despite flatly denying that he would seek immunity if indicted before the April 2019 elections, Netanyahu has unsurprisingly requested immunity to prevent his indictment from proceeding to court. Netanyahu is being charged with bribery, fraud and breach of trust for various actions he took as prime minister. I elaborated on the allegations in a previous post.

Under the Knesset Members Immunity, Rights and Duties Law of 1951 (as amended in 2005), Netanyahu may ask the Knesset to grant him functional immunity for the duration of his service on several potential grounds. Those grounds include the degree to which the acts constituting his alleged offenses were necessary for the fulfillment of his official duties; prosecutorial maleficence or discrimination; prior disciplinary action by the Knesset; and the possibility of substantial harm to the functioning of the Knesset, one of its committees, or the representation of the electorate. The last ground requires balancing between the benefits of blocking criminal proceedings and the public interest, meaning that the Knesset must consider the severity and nature of the offense in question.

Notably, the law also grants Knesset members absolute substantive immunity for any action in their capacity as a Knesset member performed while fulfilling [their] duty or in order to fulfill [their] duty. Substantive immunity is designed primarily to protect Knesset members speech and political action, and at least a portion of the graft charges against Netanyahu clearly do not meet the laws requirements. For example, it is hard to see how accepting lavish gifts in the form of champagne and cigars could be necessary for the fulfillment of Netanyahus role as prime minister. The same could be said about providing extensive regulatory benefits in return for favorable media coverage. The Knesset Committee, a subcommittee of the full parliament, has final authority to deny immunity under Article 13(c1) of the law. If the committee decides to grant immunity, however, the Knesset plenum must vote to approve its decision.

This is where things get complicated. Once the Knesset decides to dissolve itself, as it did in December 2019, its activities are restricted until a new Knesset is elected. For this reason, and because the current Knesset was elected in September before dissolving itself only three months later, the Knesset Committee has yet to be convened in its current Knesset. When it became evident that the majority of Knesset members supported convening the committee to consider Netanyahus immunity, Netanyahu launched a campaign to stall the proceedings. He appears to have concluded that he might not have a majority in favor of immunity. Netanyahus party pressured the speaker of the Knesset, Yuli Edelsteina Likud memberto invoke his authority in order to block the Knesset Committee from being convened.

It did not work. The Knessets legal adviser has concluded in a recent legal opinion that the speaker did not have authority to prevent the Knesset Committee from convening. The adviser determined that a majority of Knesset members may convene the Knesset Committee if they see fit and that, once convened, the committee is not barred from considering Netanyahus immunity even during the transitional period before the elections as long as the proceedings begin within a reasonable distance from election day, March 2.

In the meantime, the Likud party petitioned the Supreme Court to disqualify the Knessets legal adviser for conflict of interests (the advisers spouse works at the attorney generals office). The Supreme Court has rejected the Likuds request for an injunction against the publication of the opinion, thus allowing its publication, although the case is still pending. The Knessets Organizing Committee, chaired by a member of Benny Gantzs Blue and White partythe Likuds main contender for control of the governmentthen moved to convene the Knesset Committee. Nevertheless, contrary to the opinion, the Likud party and Netanyahus other supporters have continued to pressure the speaker to prevent the Knesset Committee from convening.

It is unwise to make political predictions in the current climate. But it appears that Netanyahu may not have the votes for immunity in the committee or the Knesset plenum. Reports have indicated that he is considering withdrawing his request for immunity if he concludes that he will lose.

Importantly, the indictment could advance to court even if Netanyahu is granted immunity. The Supreme Court has previously reviewedand annulleddecisions of the Knesset Committee pertaining to the immunity of other Knesset members (see, for example, Bishara v. Attorney General; HCJ 11298/03 Movement for Quality Government in Israel v. Knesset Committee). The court has framed immunity decisions as quasi-judicial decisions that are different from ordinary legislative work. Therefore, it has held, such decisions are reviewable under a lower standard of deference.

What is more, the law has changed since these cases had been decided in a way that further weakens parliamentary immunity: The default under the previous regime was that Knesset members had immunity and the attorney general had to petition the Knesset Committee to remove it. Under current law, the default is that there is no immunity, and the Knesset Committee is allowed to grant immunity upon the request of a Knesset member, with the approval of the Knesset plenum. Only two Knesset members have petitioned the committee for immunity since the law was amended, and both requests were denied. In other words, there is reason to believe that the Supreme Court might intervene should the Knesset decide to grant Netanyahu immunityafter all, there is no presumption of immunity under current law, and this is an area where the court has intervened even when there was a presumption of parliamentary immunity.

Substantive Competence

If Netanyahu does not win immunity, Israel will face a constitutional and political Pandoras box. Under current case law, Netanyahu is not legally barred from running in the upcoming elections. There are therefore two open questions: First, can he stay on as prime minister before the elections if the indictment moves forward? As mentioned previously, the attorney general has concluded that Netanyahu can remain in office as caretaker prime minister until the elections. The second question is a trickier one: What happens if Netanyahu gets the most recommendations from Knesset members in the new Knesset after the elections?

Typically, the president assigns the mandate to form a government to whoever receives the most recommendations from Knesset members, although he has discretion in making this decision under Section 7 of Basic Law: The Government:

Could the president deny Netanyahu the mandate even if he has the greatest support among Knesset members?

The Supreme Court has thus far stayed its hand on this key issue. The court has recently dismissed without prejudice a case challenging Netanyahus competence to receive the mandate to form a government after the next elections. The court ruled that the case was not ripe for adjudication because there was no certainty that Netanyahu would in fact get the mandate to form a government after the elections. The issue, it ruled, was therefore theoretical.

At the same time, the court recognized that Israel faces an unprecedented constitutional crisis and noted that the relevant constitutional questions, in principle, are justiciable. This may signal that, if Netanyahu is assigned the mandate to form a government after the elections, the court will eventually decide whether he can serve as prime minister. The court also underlined that the president, in assigning the mandate to form a government, is allowed to factor Netanyahus criminal indictment into this decisionrejecting Netanyahu's argument that the indictment should play no role. Of course, given the seven-day clock set by the Basic Law, the court has set itself up to have to produce one of the most consequential decisions in its history in less than one week.

The courts avoidance in dismissing the case is understandable given that it is caught between a rock and a hard place. The stakes of disqualifying Netanyahuthe longest serving prime minister in Israels history, who has solidified his control over the state in the course of his 11-year reign and still enjoys substantial popular and political supportare monumental. It could result in massive political blowback against the court, which has been under sustained political attacks notwithstanding the Netanyahu saga. Therefore, the court likely prefers to have Netanyahus fate decided in the political arena. If he loses the election, the court will be spared the potentially devastating consequences of deciding the competence issue. The question is what happens in the very plausible scenario that Netanyahu wins greater support in the Knesset than his main opponent, Gantz. Disqualifying him then would be even more difficult if he secures a majority on the heels of an electoral victory.

On the merits, there are conflicting considerations at play. On the one hand, effective judicial impeachment of a sitting prime minister would be unprecedented, even though Netanyahu would technically only be a caretaker prime minister until a new government is formed. As I explained previously, there is no precedent for judicial removal of a prime minister who faces criminal charges: Previous prime ministers resigned when faced with indictments. The text of the applicable constitutional normBasic Law: The Governmentrequires automatic removal only after the prime minister is convicted and the conviction becomes final, which could take years. This is different from the arrangement that applies to other officials such as ministers and mayors, which courts have previously relied on to require their removal following indictment. As I noted before,

[T]here are ample grounds for questioning the application of [precedents] to the situation of a prime minister facing criminal charges. [Previous cases] were decided based on administrative law principles that apply to the prime minister as chief executive and to city councils as administrative authorities. The question of whether a prime minister can be removed in circumstances other than those explicitly provided for in the Basic Law implicates additional complex constitutional issues. It is one thing to hold that a city councils failure to remove a mayor who is accused of criminal wrongdoing is unreasonable as a matter of administrative law. It is a completely different thing for the Supreme Court to challenge the failure of the national legislature, the Knesset, to act, should it fail to remove the prime minister . The stakes here are particularly high because the removal of the prime minister means the resignation of the entire government.

Furthermore, the provisions of the Basic Law governing the prime ministers removal due to criminal wrongdoing seem to set the bar for removal higher than the constitutional and statutory provisions that address ministers, deputy ministers and mayors. This might serve as an additional basis for distinguishing the existing precedents in the case of the prime minister. Articles 23(b) and 27 of the Basic Law provide that a government minister or deputy minister convicted of an offense with moral turpitude would automatically be removed from office once the verdict is rendered. Unlike the prime minister, they cannot remain in office until the verdict becomes final. Article 20 of the Tenure Statute provides that a mayor would be automatically suspended if convicted with moral turpitude until the verdict becomes final. No such provision exists in the Basic Law with regard to the prime minister, which indicates that the Knesset intended to bestow a more robust constitutional protection from removal upon the prime minister.

Moreover, judicial interference in this unique context creates problems for democratic legitimacy. If the court rules that Netanyahu is incompetent to serve as prime minister due to the criminal charges against him, it would essentially recognize the unelected attorney generals power to remove a prime minister by indictment.

On the other hand, judicial approval of Netanyahus competence would send the message that pervasive corruption can be tolerated, even when it directly involves alleged abuse of the office of prime minister. Such a ruling could lead to a situation in which a prime minister faces a criminal trial while overseeing and working closely with the very institutions that participate in his prosecution. It would uphold a reality that creates a serious conflict between the prime ministers self-interest and the best interests of Israel.

It would also be in tension with previous case law that required the dismissal or resignation of officials who faced serious indictments without waiting for them to be convicted, even though the Basic Law required removal only after conviction. Under existing case law, statutory removal requirements do not exhaust the circumstances in which an elected officials tenure could be terminated due to alleged criminal wrongdoing. In fact, under existing law, Netanyahu was forced to resign from the four ministerial positions he had held in addition to being prime minister. The absurdity should be evident: How can it be that Netanyahu is legally barred from serving as an ordinary minister, but not as prime minister?

Finally, Israels parliamentary system means that barring Netanyahu from receiving the mandate to form a governmentbe it by decision of the president or as a result of a subsequent Supreme Court rulingwould not necessarily abrogate the will of those who voted for the Likud party. The prime minister is not elected directly but is the member of the Knesset who succeeds in building a majority coalition. And even then, the president has discretion in granting the mandate to form a government, so a different Likud member may be able to form a government.

Focusing on the presidents decision would arguably circumvent the problemdiscussed in the excerpt aboveof overriding the Knessets decision not to remove a prime minister already serving with its confidence. The presidents exercise of his discretion in allocating the mandate to form a government could serve as a hook for judicial review. As the Supreme Court just made clear, it would be lawful for the president to consider Netanyahus indictment (and possibly his previous failures to form a government) in assigning the mandate even if Netanyahu pulls together a majority coalition after the elections.

For these reasons, while the courts wait-and-see approach may be prudent, it is also problematic. There is an argument to be made that if the court is to disqualify Netanyahu at some point, it is better to do so before the elections. First, the public has a right to know whether the head of the party they might be voting for, who personifies and tightly controls that party, is even eligible to continue as prime minister. Another round of elections that ends in deadlock because of questions and litigation about the eligibility of Netanyahu to serve as prime minister would further undermine an already fragile and nearly dysfunctional Israeli democracy.

Second, Netanyahu is currently a caretaker prime ministerthat is, prime minister by default due to the political deadlock. He does not enjoy the confidence of the Knesset, having twice tried and failed to assemble a coalition capable of receiving that confidence. From a constitutional perspective, disqualifying a prime minister in the current situation is different from disqualifying a prime minister who heads a coalition that has the support of the majority of the Knesset and thus enjoys political and public legitimacy. It would not abrogate the will of the voters, expressed through their elected officials, to the same degree as disqualifying a prime minister who enjoys the confidence of the Knesset.

But the courts decision to stay away from the matter for now means that this ship has sailed. If Netanyahu manages to secure a majority after the March elections, his political fate will come down to the outcome of the immunity vote and the presidents decisionand the likely review of these decisions by the Supreme Court. There is no telling what the political repercussions of such a constitutional showdown would be.

Follow this link:
Netanyahu and the Anatomy of a Constitutional Crisis - Lawfare

Anatomy of the GAO Trump Smear – Newsmax

The anti-Trump chorus is breathlessly declaring that the January 16 Government Accountability Office (GAO) report asserts Trump broke the law regarding Ukraine aid.

That is not what the report states and that is not what happened.

The GAO serves a vital oversight function for the Federal Government. Annually, GAO reports on waste, fraud, and mismanagement identify billions of dollars in potential savings. The Agency studiously avoids politics by outlining procedural and legal compliance issues.

GAO Report B-331564 is different, as it is incomplete on facts while overstating the Trump Administrations noncompliance with a controversial law.

The report never admits that the Ukraine Aid in question was, in fact, released on September 11, prior to the deadline of September 30, 2019.

This omission is fundamental to the entire Ukraine matter and undermines GAOs credibility.

The GAO report centers on the Impoundment Control Act (ICA). This was passed as part of Congress reining-in President Richard Nixon. Nixon had impounded funds for many programs and agencies to counter Congressional spending sprees. His actions continued a long-standing practice, going back to Thomas Jefferson, of presidents exercising fiscal discipline to thwart Congressional overspending.

The Congress took advantage of Nixons ebbing power by pushing through the ICA and other legislation to open the spending flood gates. Discretionary spending has ballooned out of control ever since.

Presidents, Republican and Democrat, have attempted to restore the balance in budgeting and spending policy. The GAOs Ukraine report cites numerous court cases where Clinton and other presidents have sought court assistance to set limits and clarify processes.

All funds were released prior to the Congressional deadline. The delay in releasing Ukraine funds never crossed these legal lines.

In fact, the delays fully complied with the law authorizing the funds (PL 115-232), as it explicitly stated that, In order to obligate more than fifty percent of the amount appropriated, DOD was also required to certify to Congress that Ukraine had taken substantial actions on defense institutional reforms.

The Office of Management and Budget (OMB) issued numerous apportionment schedules with footnotes explaining the delay in releasing the funds was to allow for an interagency process to determine best use of such funds. Each memo consistently stated that, this brief pause in obligations will not preclude DODs timely execution of the final policy direction.

One part of the foreign military financing (FMF) earmarked for Ukraine was delayed only six days.

The GAO Ukraine report, clearly states that:

The President may temporarily withhold funds from obligationbut not beyond the end of the fiscal year in which the President transmits the special messageby proposing a deferral. 2 U.S.C. 684

At no point in the Ukraine Report does the GAO find that OMB or the president triggered a deferral or impoundment. Therefore, there was no violation of the Impoundment Control Act (ICA).

However, the GAO pours through countless memos from the OMB, as well as OMB responses to GAO questions. Unfortunately, OMBs responses dug avoidable holes into which the Trump Administration fell by raising needless challenges to the ICA.

OMB engaged in a battle it did not need to fight. This triggered GAO having to recount the ICA battles from other Administrations and pointing out the flaws in OMBs arguments. OMB responded by not responding. As the GAO-OMB dialogue dissipated, political rhetoric seeped-in.

The GAO stepped over their line by asserting there may be potential impoundments where none exist. You either impound or you dont. There is no potential. The GAO ascribes policy reasons for the delay of funds without providing any evidence.

Finally, to carve out its own place in the Impeachment, the GAO violated decades of its own professional code of conduct by declaring, We consider a reluctance to provide a fulsome response to have constitutional significance.

Senator Chris Van Hollen (D-MD), a dedicated Never-Trumper, requested the GAO Ukraine report on October 30, 2019. He kept demanding GAO provide a report sooner versus later in a letter dated December 23, 2019. The GAO admits that its report is a work in progress and states it is waiting on additional information from the State Department and OMB.

Unfortunately, Thomas Armstrong, GAO General Counsel, was willing to risk the agencys reputation as the gold standard of oversight, by prematurely releasing an incomplete and flawed report, immediately relegating it to just another politically charged smear.

Scot Faulkner is the best-selling author of: "Naked Emperors: The Failure of the Republican Revolution." He also served as the first chief administrative officer of the U.S. House, and was director of personnel for the Reagan campaign and went on to serve in the presidential transition team and on the White House staff. During the Reagan administration, he held executive positions at the FAA, the GSA, and the Peace Corps. Read more of Scot Faulker, Go Here Now.

2020 Newsmax. All rights reserved.

Follow this link:
Anatomy of the GAO Trump Smear - Newsmax

Greys Anatomy Time Jump Twist: The Season 16 Premiere Will Choose Up – Sunriseread

Grays Anatomy will likely be doing the time warp once more when it returns for Season 16 later this month, however theres a catch.

Showrunner Krista Vernoff tells TVLine that the Thursday, Sept. 26, opener will decide up moments from the place we left off within the Season 15 finale, and the entire lingering cliffhangers i.e. Meredith, Richard and Alex receiving pink slips, DeLuca sporting jail orange and Jackson vanishing into skinny air thick fog will likely be addressed fairly instantly.

However shortly thereafter, the clock will start to tick however rapidly. Well then span just a little little bit of time over the course of the hour, reveals Vernoff by the use of describing the weird time-jump situation. How a lot time will lapse by the top of the premiere? I might slightly not reveal that, she says, holding her playing cards near her vest.

Whatever the leap aheads precise size (be it weeks or months or years?), Vernoff guarantees that there will likely be fallout from the varied conflicts significantly the place Meredith and DeLuca are involved.

Theyve acquired to navigate the complexities of a brand new relationship within the wake of Meredith having been fired and having damaged the regulation, previews the EP. There are stressors on their very new relationship coming from the ramifications of these choices final season.

For extra intel on Grays Anatomys 16th season, try TVLines densely-packed, just-published Fall Preview Scoop Spectacular.

Read more:
Greys Anatomy Time Jump Twist: The Season 16 Premiere Will Choose Up - Sunriseread